NEW YORK (GenomeWeb) – Quest Diagnostics announced today it will offer BioMérieux's BRAF mutation companion diagnostic for two of GlaxoSmithKline's molecularly targeted melanoma drugs, Tafinlar (dabrafenib) and Mekinist (trametinib).
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.